Factors affecting 131I-Lym-1 pharmacokinetics and radiationdosimetry in patients with non-Hodgkin's lymphoma and chroniclymphocytic leukemia

Journal of Nuclear Medicine

Volumn 40, Issue 8, 1999, Pages 1317-1326

  DeNardo, Gerald L ^a   DeNardo, Sally J ^b   Shen, Sui ^b   DeNardo, Diane A ^b   Mirick, Gary R ^b   Macey, Daniel J ^b   Lamborn, Kathleen R ^b  

^a Molecular Cancer Institute   (United States)

^b NONE

Author keywords

131I; Antibody; Cancer; Dosimetry; Radioimmunotherapy

Indexed keywords

IODINE 131; MONOCLONAL ANTIBODY; LACTATE DEHYDROGENASE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CHRONIC LYMPHATIC LEUKEMIA; DOSE RESPONSE; DOSIMETRY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; SURVIVAL RATE; TUMOR VOLUME; BINDING SITE; BLOOD; CLINICAL TRIAL; MIDDLE AGED; RADIOMETRY; SPLENECTOMY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; BINDING SITES; FEMALE; HUMANS; IODINE RADIOISOTOPES; L-LACTATE DEHYDROGENASE; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; SPLENECTOMY;

EID: 0032587116     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Armitage JO. Treatment of non-Hodgkin's lymphoma. N Engl J Med. 1993;328: 1023-1030.
2. Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res. 1992;52:5432s-5440s.
3. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B-cell lymphoma by 1-131 Lym-1 monoclonal antibodies. Int J Biol Markers. 1987;2:49-53.
4. 131I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol. 1998;16:3246-3256.
5. 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B-cell lymphomas. Lancet. 1995;346:336-340.
6. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974-1981.
7. Goldenberg DM, Horowitz JA, Sharkey RM, el al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol. 1991;9:548-564.
8. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996;2:457-470.
9. 131I-Lym-1 antibody. Cancer Biother Radiopharm. 1998;13:239-254.
10. Vriesendorp HM, Herpst JM, Germack MA, et al. Phase I-II studies of yttrium-labeled antiferritin treatment for end-stage Hodgkin's disease, including radiation therapy oncology group 87-01. J Clin Oncol. 1991;9:918-928.
11. Scheinberg DA, Lovett D, Divgi CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol. 1991;9:478-490.
12. DeNardo GL, Lewis JP, DeNardo SJ, O'Grady LF. Effect of Lym-1 radioimmunoconjugate on refractory chronic lymphocytic leukemia. Cancer. 1994;73:1425-1432.
13. Kuzel T, Rosen ST, Zimmer AM, et al. A phase 1 escalating-dose safety, dosimetry and efficacy study of radiolabeled monoclonal antibody Lym-1. Cancer Biother. 1993;8:3-16.
14. 131I-Lym-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconj Radiopharm. 1993;6:1-11.
15. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. Cancer. 1982;49:2112-2135.
16. DeNardo DA, DeNardo GL, Yuan A, et al. Prediction of radiation doses from therapy using tracer studies with iodine-131 labeled antibodies. J Nucl Med. 1996;37:1970-1975.
17. Rose LM, Gunasekera AH, DeNardo SJ, DeNardo GL, Meares CF. Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother. 1996;43:26-30.
18. Epstein AL, Marder RJ, Winter JN, et al. Two new monoclonal antibodies, Lym-1 and Lym-2, reactive with human-B-lymphocytes and derived tumors, with immunodiagnostic and immunotherapeutic potential. Cancer Res. 1987;47:830-840.
19. DeNardo GL, DeNardo SJ, Macey DJ, et al. Quantitative pharmacokinetics of radiolabeled monoclonal antibodies for imaging and therapy in patients. In: Srivastava SC, ed. Radiolabeled Monoclonal Antibodies for Imaging and Therapy. New York, NY: Plenum: 1988:293-310.
20. 131I-Lym-1 in patients with B-cell malignancies. Nucl Med Commun. 1993;14:587-595.
21. Erwin WD, Groch MW, Macey DJ, DeNardo GL, DeNardo SJ, Shen S. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol. 1996;23:525-532.
22. Sorenson JA. Methods of correcting Anger camera deadtime losses. J Nucl Med. 1976;17:127-141.
23. Thomas SR, Maxon HR, Kereiakes JG. In vivo quantitation of lesion radioactivity using external counting methods. Med Phys. 1976;3:253-255.
24. Eary JF, Appelbaum FL, Durack L, Brown P. Preliminary validation of the opposing view method for quantitative gamma camera imaging. Med Phys. 1989;16:382-387.
25. Macey DJ, DeNardo SJ, DeNardo GL, DeNardo DA, Shen S. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med. 1995;20:117-125.
26. Loevinger R, Berman M. A Revised Schema for Calculating the Absorbed Dose from Biologically Distributed Radionuclides. Medical Internal Radiation Dose Pamphlet No. 1. New York, NY: Society of Nuclear Medicine; 1976:1-10.
27. Snyder WS, Ford MR, Warner GG. "S" Absorbed Dose per Unit Cumulated Activity for Selected Radionuclides and Organs. Medical Internal Radiation Dose Pamphlet No. 11. New York, NY: Society of Nuclear Medicine; 1975:82-83.
28. Shen S, DeNardo GL, O'Donnell RT, Yuan A, DeNardo DA, DeNardo SJ. Impact of splenomegaly on therapeutic response and I-131-LYM-1 dosimetry in patients with B-lymphocytic malignancies. Cancer. 1997;80(suppl):2553-2558.
29. Lim S-M, DeNardo GL, DeNardo DA, et al. Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources. J Nucl Med. 1997;38:1374-1378.
30. Hollander M, Wolfe DA. Nonparametric Statistical Methods. New York, NY: Wiley; 1973:120.
31. DeNardo GL, DeNardo SJ. Perspectives on the future of radioimmunodiagnosis and radioimmunotherapy of cancer. In: Burchiel SW, Rhodes BA, eds. Radioimmunoimaging and Radioimmunotherapy. New York, NY: Elsevier Science; 1983:41-62.
32. Jain RK. Barriers to drug delivery in solid tumors. Sci Am. 1994;271:58-65.
33. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med. 1992;33:1648-1653.
34. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst. 1990;82: 763-771.
35. Buchsbaum DJ, Khazaeli MB, Liu TP, Bright S. Fractionated radioimmunotherapy of human colon carcinoma xenografts with I-131-labeled monoclonal antibody CC49. Cancer Res. 1995;55(suppl):5881-5887.
36. 131I] anti-B1 (anti-CD20) antibody. N Engl J Med. 1993;329:459-465.
37. Siegel JA, Lee RE, Pawlyk DA, Horowitz JA, Sharkey RM, Goldenberg DM. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy. Int J Rad Appl Inarum [B]. 1989;16:553-559.
38. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med. 1993;329:1219-1224.
39. Shen S, DeNardo GL, DeNardo SJ, Yuan A, DeNardo DA, Lamborn KR. Reproducibility of operator processing for radiation dosimetry. Nucl Med Biol. 1997;24:77-83.
40. Shen S, DeNardo GL, Macey DJ, et al. Practical determination of organ S values for individual patients for therapy. Nucl Med Biol. 1997;24:447-449.